| N.J.'s Congressman Saxton to retire
U.S. Rep. James Saxton (R., Mount Holly), who worked tirelessly to save local military bases from federal budget cuts, said today that he has decided not to run for re-election in 2008 because of his health. "Although I had intended to run in 2008 and was planning a strong campaign, developments which occurred earlier this year regarding my health have prompted me to make this decision," said a statement today from Saxton, a former public school teacher, business owner, state senator and state assemblyman who has never lost an election. "I plan to serve out the remainder of my current term in the 110th Congress," he said. "I will continue to receive medical treatment, and my health care providers have indicated the prognosis is, in fact, very positive." Saxton, who will be 66 when the current term ends, has been treated for prostate cancer.
Israeli Prime Minister Olmert discloses he has 'treatable' prostate ...
Olmert, who is 62, called in reporters Monday and disclosed, calmly and matter-of-factly, that he has a cancerous tumor in his prostate gland, and he will have to undergo surgery to remove it. There is never a good time for such news, but the announcement comes at a particularly sensitive time -- just as preparations are in full swing for a Mideast conference in the U.S., called by President Bush to push Israeli-Palestinian peace efforts forward. Olmert insisted the ailment and its treatment will not detract from his ability to run his country, and U.S. and European officials said his condition was not likely to delay the gathering. Olmert's Palestinian counterpart in the talks, President Mahmoud Abbas himself battled prostate cancer, undergoing surgery in Washington in 2001.
Pharmacopeia Acquires Selective Androgen Receptor Modulator ('SARM ...
PRINCETON, N.J., Oct. 15 /PRNewswire-FirstCall/ -- Pharmacopeia (NASDAQ: PCOP) , an innovator in the discovery and development of novel small molecule therapeutics, today announced that it has licensed from Bristol-Myers Squibb (NYSE: BMY) a selective androgen receptor modulator (SARM) program, including a lead compound in Phase 1 clinical development and back-up compounds. PS178990 is a non-steroidal selective androgen receptor modulator, or SARM, which was designed to provide the benefits of testosterone without its unwanted side effects on prostate. The program has completed a Phase 1 single ascending dose study. SARM agonists are a potential novel treatment for muscle wasting associated with a number of serious chronic and acute medical conditions such as surgical and severe burn recovery, end-stage renal disease and cancer- and AIDS-related cachexia.
|
